Budesonide oral suspension,
does it really help with 12-week histologic response in eosinophilic esophagitis?
research showsThe grade is C. In 318 phase 3 participants, stringent histologic response was 53.5% versus 1.0%, difference 53 points (95% CI 43.8 to 59.5). The co-primary symptom response also succeeded, 52.6% versus 39.1%, difference 13 points (95% CI 1.6 to 24.3), so there is no co-primary split.
ads claimHistologic normalization and patient-experienced dysphagia should be reported separately and not expanded into durable remission.
Useful facts when choosing a product
- The histologic-response absolute difference was 53 points.
- The EREFS between-group change was -1.8 points; lower is better.
What the research actually shows
The trial randomized 318 patients aged 11 to 55 in a 2:1 ratio to budesonide 2 mg twice daily or placebo. Both co-primary endpoints succeeded. Axis 6 B0 evidence ① Allocation concealment: "randomized 2:1" using central assignment ② Blinding: "double-blind, placebo-controlled" ③ Analysis population and missingness: "full analysis set included all randomized patients who received at least 1 dose" ④ Prespecified primary endpoint: "Co-primary endpoints were ... histologic responders ... or dysphagia symptom responders" - consistent with NCT02605837 Shire/Takeda funded the program. Higher DSQ and EREFS are worse. Swallowed topical steroids are used for EoE in Korea, but Korean approval of this oral-suspension formulation could not be confirmed in the public sources checked.
Why this is classified as C (54)
One manufacturer-funded 12-week histologic-surrogate trial gives C with 54 points.
Counterpoint. Both co-primary endpoints succeeded, but long-term outcomes remain separate.
Rejudgment record. New verdict — Histologic surrogate in one manufacturer-funded 12-week phase 3 trial, with both co-primary endpoints successful
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| 12-week histologic response | C | Rates were 53.5% versus 1.0%. |
| 12-week DSQ symptom response | C | Rates were 52.6% versus 39.1%, meeting the co-primary endpoint. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Phase 3 double-blind randomized placebo-controlled trial | 105 | Funded by Shire/Takeda | Co-primary 12-week histologic and DSQ symptom responses | Histology 53.5% versus 1.0%, +53 points (95% CI 43.8 to 59.5); symptoms 52.6% versus 39.1%, +13 points (95% CI 1.6 to 24.3). | Pivotal phase 3 surrogate evidence |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of Budesonide Oral Suspension for 12-Week Histologic Response in Eosinophilic Esophagitis, a Surrogate Outcome — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/budesonide-oral-suspension-eoe-histologic-response/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.